Skip to main content
Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy.
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.
ICYMI: Sex related differences in PsA

Different factors are known to influence disease characteristics and outcomes in

Dr. John Cush RheumNow

1 year 9 months ago
ICYMI: Sex related differences in PsA Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and… https://t.co/60vdbWLltB https://t.co/nY1CuJhKMb
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but olde

Dr. John Cush RheumNow

1 year 9 months ago
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/pqfmFGT0D6 https://t.co/zo0APuAcQS
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Os

Dr. John Cush RheumNow

1 year 9 months ago
3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS
U.S. Preventive Services Task Force (USPSTF) has recommended AGAINST use of vitamin D +/- Ca for the primary prevention

Dr. John Cush RheumNow

1 year 9 months ago
U.S. Preventive Services Task Force (USPSTF) has recommended AGAINST use of vitamin D +/- Ca for the primary prevention of fractures (or falls) in postmenopausal women/men > 60 years of age. or older.https://t.co/1bUBqTVaX0 https://t.co/AXWxduVkOT
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease:

➡️ A. Ogdie: Prevent

Dr. John Cush RheumNow

1 year 9 months ago
RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease: ➡️ A. Ogdie: Preventing PsA ➡️ A. Kavanaugh: Biologic Therapies ➡️ K. Gordon: Head-to-Head Studies Register now! https://t.co/BTLmc8HSKY https://t.co/KVsLF3yOZx
ICYMI: Beyond the Needle: Redefining the Assessment of Lupus Nephritis

Lupus nephritis is one of the most silent and s

Dr. John Cush RheumNow

1 year 9 months ago
ICYMI: Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). When not captured early, patients are at high risk of progressing to end-stage renal disease, which… https://t.co/ctngE0bMkX https://t.co/koDBZaPc19
Assessment of axSpA
Approximately 12 million US adults in the US have gout. Two recent literature reports in JAMA and Arthritis Care & Research highlight contributors to gout flares.
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.
Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing certain hospitals and for-profit pharmacies to exploit the program.
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome

Dr. Mike Putman reports on abstract 2527, Efficacy and Safet

Dr. John Cush RheumNow

1 year 9 months ago
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled,… https://t.co/kkIOCUZRml https://t.co/nL47c5veCp
×